Abstract
Objective: The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. Design: Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. Results: 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. Conclusion: FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
| Original language | English |
|---|---|
| Journal | Gut |
| DOIs | |
| Publication status | Accepted/In press - 01-01-2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
Cite this
}
Scientific frontiers in faecal microbiota transplantation : Joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). / Ng, Siew C.; Kamm, Michael A.; Yeoh, Yun Kit; Chan, Paul K.S.; Zuo, Tao; Tang, Whitney; Sood, Ajit; Andoh, Akira; Ohmiya, Naoki; Zhou, Yongjian; Ooi, Choon Jin; Mahachai, Varocha; Wu, Chun Ying; Zhang, Faming; Sugano, Kentaro; Chan, Francis K.L.
In: Gut, 01.01.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - Scientific frontiers in faecal microbiota transplantation
T2 - Joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE)
AU - Ng, Siew C.
AU - Kamm, Michael A.
AU - Yeoh, Yun Kit
AU - Chan, Paul K.S.
AU - Zuo, Tao
AU - Tang, Whitney
AU - Sood, Ajit
AU - Andoh, Akira
AU - Ohmiya, Naoki
AU - Zhou, Yongjian
AU - Ooi, Choon Jin
AU - Mahachai, Varocha
AU - Wu, Chun Ying
AU - Zhang, Faming
AU - Sugano, Kentaro
AU - Chan, Francis K.L.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objective: The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. Design: Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. Results: 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. Conclusion: FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
AB - Objective: The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. Design: Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. Results: 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. Conclusion: FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.
UR - http://www.scopus.com/inward/record.url?scp=85073741227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073741227&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2019-319407
DO - 10.1136/gutjnl-2019-319407
M3 - Article
C2 - 31611298
AN - SCOPUS:85073741227
JO - Gut
JF - Gut
SN - 0017-5749
ER -